Trelegy Ellipta can be prescribed at general hospitals

It passed DC of 38 medical institutions nationwide, including SNUH and AMC

In a study reflecting the clinical practice environment, the efficacy of improving lung function was confirmed

The COPD treatment Trelegy Ellipta can be prescribed at general hospitals.

 

According to related industries, GSK Korea's COPA treatment Trelegy Ellipta (Fluticasone Furoate, Umecridinium Br, Villanterol Trifenate) passed DC at 38 medical institutions including Big 5 General Hospitals such as Seoul National University Hospital and Asan Medical Center.

 

Since the insurance benefits in June, prescriptions have become possible quickly.

 

Trelegy Ellipta is the first COPD complex approved in Korea in May 2018.

 

It is prescribed as a maintenance therapy for moderate and severe COPD that is not properly controlled by persistent β2 agonist and inhalation corticosteroid combination therapy or LABA and LAMA combination therapy in adults.

 

As for the benefit criteria, despite ▲ persistent beta 2 agonist and LAMA combination therapy, if FEV1 value is less than 60% of the normal prediction or acute exacerbation occurs more than twice a year, ▲If symptoms such as dyspnea are not properly controlled despite persistent beta 2 agonist and inhalation corticosteroid combination therapy, ▲If a patient who is simultaneously administering Vilanterol trifenate/Fluticasone furoate and Umecridinium Br satisfies each individual examination, this is the case when pt wants to switch to Trelegy.

 

The validity of Trelegy Ellipta has been reaffirmed through a recent INTREPID phase 4 study.

 

The study was conducted at 147 centers in five European countries, including the UK and Germany, with a total of 3,092 COPD patients participating.

 

Patients were assigned to the Trelegy Ellipta treatment group and the multiple inhalation type three-drug combination treatment group on a one-to-one basis.

 

The primary efficacy evaluation variable was the COPD Assessment Test (CAT) score, which is the COPD evaluation test, to evaluate patients' health status.

 

As a result of measuring the ratio of patients whose CAT score decreased by more than 2 units to baseline at the 24th week of treatment, the median CAT score in the patient group treated with Trelegy Ellipta was 18.0 (8.0), and the median CAT score in the multiple inhalation groups was 19.1 (7.9), significantly improving overall health.

 

The secondary efficacy evaluation variable based on the sub-analysis was the change in FEV1 identified at week 24 of treatment and the proportion of patients who committed more than one serious error when using each inhaler.

 

As a result of the analysis, FEV1 in the Trelegy Ellipta treatment group was 77 mL, which showed statistically superior lung function improvement compared to the multiple inhalation treatment group (28 mL).